Jean-Marie Cuillerot - Jan 11, 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Medical Officer
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Jan 11, 2024
Transactions value $
$0
Form type
4
Date filed
1/16/2024, 04:45 PM
Previous filing
Jan 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +99.3K $0.00 99.3K Jan 11, 2024 Common Stock 99.3K $4.82 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option shall vest on February 1, 2025, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.